Drug Patents owned by Merck
1. List of Emend drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 26 March, 2003
Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy
Dosage: CAPSULE;ORAL
2. List of Zolinza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7456219 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7652069 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(26 days from now) | |
| US7732490 | MERCK | Methods of treating cancer |
Mar, 2023
(26 days from now) | |
| US8067472 | MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(26 days from now) | |
| US8101663 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(26 days from now) | |
| US7851509 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(1 year, 15 days from now) | |
| US7399787 | MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(2 years from now) | |
| US8093295 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(3 years from now) | |
| US8450372 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(5 years from now) | |
Drugs and Companies using VORINOSTAT ingredient
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic